Diagnolita - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | - | 17,012 | 18,405 | 890,747 | 1,277,030 | 32,025 | 28,563 | 34,702 |
| Profit before tax | - | - | - | - | - | - | - | - |
| Net profit | -47,500 | -108,692 | -248,025 | 711,192 | 635,141 | -283,231 | -392,367 | -353,257 |
| Equity | 364,468 | 233,621 | 93,116 | 804,308 | 1,439,449 | 1,156,218 | 763,851 | 410,593 |
| Liabilities | 538,315 | 819,622 | 30,695 | 88,370 | 138,577 | 25,374 | 33,768 | 33,541 |
| Non-current assets | 21,659 | 56,615 | 41,388 | 64,681 | 134,333 | 96,262 | 53,148 | 24,524 |
| Current assets | 880,083 | 996,451 | 115,239 | 846,310 | 1,458,366 | 1,085,250 | 744,154 | 416,368 |
| Total assets | 901,742 | 1,053,066 | 156,627 | 910,991 | 1,592,699 | 1,181,512 | 797,302 | 440,892 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 141,165 | 40,355 | 78 |
| Social insurance contributions | - | - | - | - | - | 46,660 | 47,151 | 46,852 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | - | +8.2% | +4739.7% | +43.4% | -97.5% | -10.8% | +21.5% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -5.3% | -10.3% | -158.4% | 78.1% | 39.9% | -24.0% | -49.2% | -80.1% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -13.0% | -46.5% | -266.4% | 88.4% | 44.1% | -24.5% | -51.4% | -86.0% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | -638.9% | -1347.6% | 79.8% | 49.7% | -884.4% | -1373.7% | -1018.0% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 1.5 | 3.5 | 0.3 | 0.1 | 0.1 | 0.0 | 0.0 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | 2,520 | 2,598 | 111,343 | 163,026 | 5,264 | 4,761 | 5,784 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Diagnolita - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-06-16 | 2026-06-25 | 4133.58 |
| 2022-08-23 | 2022-09-08 | 0.01 |
| 2022-06-16 | 2022-07-06 | 0.01 |
| 2022-05-17 | 2022-06-08 | 0.02 |
| 2022-04-19 | 2022-05-09 | 0.02 |
| 2022-03-16 | 2022-04-12 | 0.01 |
| 2022-02-17 | 2022-03-07 | 0.01 |
| 2022-01-31 | 2022-02-07 | 0.01 |
| 2021-12-03 | 2021-12-07 | 0.80 |
Diagnolita - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Diagnolita, UAB (code 303128944) is a Private Limited Liability Company engaged in research and development in natural sciences. In 2025, the company generated EUR 34.7K in revenue, up 21.5% year on year and 8.4% over two years. Despite this modest revenue base, it reported a net loss of EUR 353.3K, following losses of EUR 392.4K in 2024 and EUR 283.2K in 2023. The revenue trend improved in 2025 after a decline in 2024, but profitability remained under pressure throughout the period. The company’s balance sheet contracted materially: total assets decreased from EUR 1.18M in 2023 to EUR 440.9K in 2025, while equity fell from EUR 1.16M to EUR 410.6K. Liabilities stayed low at EUR 33.5K in 2025, supporting a high equity ratio of 93.1% and a low debt-to-equity level of 0.08. Asset turnover remained weak at 0.08x, reflecting limited revenue generation relative to the asset base. Revenue per employee stood at EUR 5.8K in 2025, indicating low operational scale.